- Home
- ACET vs ICCH Comparison
ACET vs ICCH Comparison
Compare ACET & ICCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- ICCH
- Stock Information
- Founded
- ACET 1947
- ICCH 1950
- Country
- ACET United States
- ICCH United States
- Employees
- ACET N/A
- ICCH N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- ICCH Property-Casualty Insurers
- Sector
- ACET Health Care
- ICCH Finance
- Exchange
- ACET Nasdaq
- ICCH Nasdaq
- Market Cap
- ACET 75.6M
- ICCH 68.8M
- IPO Year
- ACET N/A
- ICCH 2017
- Fundamental
- Price
- ACET $0.91
- ICCH $23.25
- Analyst Decision
- ACET Strong Buy
- ICCH
- Analyst Count
- ACET 4
- ICCH 0
- Target Price
- ACET $5.67
- ICCH N/A
- AVG Volume (30 Days)
- ACET 513.3K
- ICCH 5.7K
- Earning Date
- ACET 11-06-2024
- ICCH 03-03-2025
- Dividend Yield
- ACET N/A
- ICCH N/A
- EPS Growth
- ACET N/A
- ICCH 42.86
- EPS
- ACET N/A
- ICCH 2.16
- Revenue
- ACET N/A
- ICCH $92,541,259.00
- Revenue This Year
- ACET N/A
- ICCH N/A
- Revenue Next Year
- ACET N/A
- ICCH N/A
- P/E Ratio
- ACET N/A
- ICCH $10.77
- Revenue Growth
- ACET N/A
- ICCH 14.09
- 52 Week Low
- ACET $0.81
- ICCH $14.78
- 52 Week High
- ACET $3.62
- ICCH $23.96
- Technical
- Relative Strength Index (RSI)
- ACET 43.86
- ICCH 47.12
- Support Level
- ACET $0.85
- ICCH $23.28
- Resistance Level
- ACET $0.94
- ICCH $23.47
- Average True Range (ATR)
- ACET 0.08
- ICCH 0.06
- MACD
- ACET 0.00
- ICCH -0.02
- Stochastic Oscillator
- ACET 22.16
- ICCH 10.20
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About ICCH ICC Holdings Inc.
ICC Holdings Inc is a specialty insurance carrier underwriting commercial multi-peril, liquor liability, worker's compensation, and umbrella liability coverages for the food and beverage industry. The company markets its products through a network of independent agents in Colorado, Illinois, Indiana, Iowa, Kansas, Minnesota, Missouri, Pennsylvania, Ohio, and Wisconsin.